Dose Escalation Study for Defining the Maximum Tolerated Dose of Continuous Oral Trofosfamide in Pretreated Patients with Metastatic Lung Cancer

Publisher： Karger

E-ISSN： 2296-5262|27|6|534-538

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.27, Iss.6, 2004-12, pp. : 534-538

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Oral Trofosfamide in Elderly and/or Heavily Pretreated Patients with Metastatic Lung Cancer

By  

Oncology Research and Treatment, Vol. 23, Iss. 4, 2000-09 ,pp. : 341-344

Karger

Access to resources Recommend Favorite

Continuous Administration of Daily Low-Dose Temozolomide in Pretreated Patients with Advanced Non-Small Cell Lung Cancer: A Phase II Study

By  

Oncology, Vol. 76, Iss. 2, 2009-01 ,pp. : 112-117

Karger

Access to resources Recommend Favorite

Dose Escalation Study of Amrubicin in Combination with Fixed-Dose Irinotecan in Patients with Extensive Small-Cell Lung Cancer

By  

Oncology, Vol. 74, Iss. 1-2, 2008-06 ,pp. : 7-11

Karger

Access to resources Recommend Favorite

Dose Escalation Study of Paclitaxel in Combination with Fixed-Dose Irinotecan in Patients with Advanced Non-Small Cell Lung Cancer (JCOG 9807)

By  

Oncology, Vol. 66, Iss. 2, 2004-05 ,pp. : 94-100

Karger

Access to resources Recommend Favorite

A Dose Escalation Study of Biweekly Oral Vinorelbine and Gemcitabine in Patients with Solid Tumors

By  

Oncology, Vol. 71, Iss. 5-6, 2007-09 ,pp. : 347-353

Karger

Access to resources Recommend Favorite